ClinicalTrials.Veeva

Menu

Proton Pump Inhibitors Use in Patients With Psoriasis

E

EMS

Status and phase

Withdrawn
Phase 4

Conditions

Psoriasis

Treatments

Drug: esomeprazole
Drug: desonide

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

Full description

Proton pump inhibitors act in blocking acid secretion and also have antioxidant and anti-inflammatory properties. For that mechanisms possibly PPIs may have an anti-inflammatory action with improvement in skin lesions in patients with psoriasis.

The study will assess the evolution of skin lesions in psoriasis patients using PPIs

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnostic of Psoriasis

Exclusion criteria

  • Pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups

Group A
Experimental group
Description:
Proton Pump Inhibitor esomeprazole 40 mg twice a day
Treatment:
Drug: esomeprazole
Group B
Active Comparator group
Description:
desonide
Treatment:
Drug: desonide

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems